Lexeo Therapeutics, Inc.
LXEO
$4.84
-$0.12-2.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -87.27M | -87.50M | -99.96M | -104.97M | -114.17M |
| Total Depreciation and Amortization | 2.17M | 2.12M | 2.08M | 2.06M | 2.04M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.84M | 7.84M | 8.84M | 9.62M | 10.70M |
| Change in Net Operating Assets | -17.11M | -20.45M | -9.52M | -13.52M | 6.37M |
| Cash from Operations | -88.37M | -97.99M | -98.56M | -106.81M | -95.07M |
| Capital Expenditure | -331.00K | -432.00K | -397.00K | -397.00K | -191.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -24.62M | -77.96M | -89.86M | -81.75M | -117.05M |
| Cash from Investing | -24.95M | -78.39M | -90.25M | -82.15M | -117.24M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -515.00K | -495.00K | -533.00K | -480.00K | -508.00K |
| Issuance of Common Stock | 181.83M | 236.51M | 234.08M | 80.33M | 80.23M |
| Repurchase of Common Stock | -- | -- | -- | -4.00K | -4.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -10.64M | -16.78M | -16.75M | -6.92M | -6.92M |
| Cash from Financing | 170.68M | 219.24M | 216.80M | 72.93M | 72.80M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 57.35M | 42.86M | 27.98M | -116.03M | -139.51M |